Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Health Syst Pharm ; 77(Supplement_1): S19-S24, 2020 Feb 19.
Article in English | MEDLINE | ID: mdl-31960026

ABSTRACT

PURPOSE: Results of a study evaluating the impact of privileging pharmacists to manage microbiologic test results for patients discharged from the emergency department (ED) are reported. METHODS: This was a single-center, retrospective pre-post study that was conducted at an urban academic medical center. Patients discharged from the ED with a subsequent positive microbiologic test result before and after privileging of an ED specialty practice pharmacist (ED-SPP) to manage the results independently were screened for inclusion. Time to patient notification of a required change in antimicrobial therapy was compared between groups. Numbers of erroneous interventions before and after pharmacist privileging were compared to assess the safety of implementation. RESULTS: One hundred seventy-eight positive microbiologic test results (n = 92 pre- and n = 86 postimplementation) were included. The median time to patient notification in the pre-implementation group was 23.6 hours (range, 12.4-93 hours) and in the postimplementation group was 14.9 hours (range, 2.5-27.9 hours; P = 0.0023). As determined by the board-certified infectious disease physician, 1.1% of reviewed microbiologic test results (1 of 92) was erroneous prior to implementation of pharmacist privileging compared with 2.3% (2 of 86) after implementation (P = 0.6105). CONCLUSION: Privileging ED-SPPs to assess microbiologic test results improved the time to patient notification with no statistical difference in the number of erroneous interventions between groups. These findings demonstrate the benefit of clinical privileging and provide support for expansion of this role to other ED-SPPs.


Subject(s)
Anti-Infective Agents/administration & dosage , Emergency Service, Hospital , Pharmacists/organization & administration , Pharmacy Service, Hospital/organization & administration , Academic Medical Centers , Humans , Microbiological Techniques , Patient Discharge , Professional Role , Retrospective Studies , Time Factors
2.
Am J Health Syst Pharm ; 73(3): 121-5, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26796904

ABSTRACT

PURPOSE: The results of a study to assess the financial impact of an automatic formulary substitution of ipratropium-albuterol nebulization solution for ipratropium-albuterol metered-dose inhalers (MDIs) at an academic health system are reported. METHODS: The study was conducted at a 1242-bed urban academic health system. Data were collected regarding all respiratory medication administrations during a three-month period before the MDI-to-nebulizer substitution (October-December 2012) and the same period of 2013 (after the substitution was implemented). Purchasing data were compared between the two time periods to measure the impact of the formulary substitution on pharmacy department costs, and documented administrations were assessed to evaluate associated changes in respiratory therapist (RT) workload. RESULTS: With 100% prescriber compliance with the formulary substitution, the number of MDI administrations of ipratropium-albuterol declined from 13,667 in October-December 2012 to zero in the same period of 2013. The substitution required expenditures for equipment (vibrating mesh nebulizer technology and patient-specific kits) and RT personnel (one additional RT was hired), but those added costs were substantially outweighed by cost savings resulting from a substantial reduction in overall respiratory drug spending. CONCLUSION: An automatic substitution of ipratropium-albuterol nebulization solution for MDIs resulted in a three-month savings of $99,359 in drug cost and an extrapolated full-year savings of $397,436. When additional costs associated with the substitution were taken into account, there was an overall savings of $146,806 during the implementation year and a projected savings of $257,936 for each following year.


Subject(s)
Chemistry, Pharmaceutical/economics , Cost-Benefit Analysis , Drug Costs , Lung Diseases, Obstructive/drug therapy , Nebulizers and Vaporizers/economics , Administration, Inhalation , Albuterol/administration & dosage , Bronchodilator Agents/administration & dosage , Drug Therapy, Combination/economics , Hospitals, University , Humans , Ipratropium/administration & dosage , Ohio
3.
Hosp Pharm ; 50(3): 243-6, 2015 Mar.
Article in English | MEDLINE | ID: mdl-26405315

ABSTRACT

Learning through the examples of great leaders can provide pharmacy directors with guidance on how to shape their leadership style. John D. Rockefeller was one of the most successful businessmen in the world, and he is highly regarded as having been a great leader. His example of having the courage of his convictions will be necessary as pharmacy faces drastic changes ahead in pharmacy provider status and practice model changes. His management of his staff serves as an excellent example of the importance of staff retention programs. As health systems strive to do more with less, it is now more important than ever to scrutinize using resources and apply Rockefeller's attention to efficiency and effectiveness when growing patient-centered pharmacy services.

SELECTION OF CITATIONS
SEARCH DETAIL
...